This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

QVC And Fashion Footwear Association Of New York Invest In Personalized Breast Cancer Therapy Research

WEST CHESTER, Pa., April 4, 2013 /PRNewswire/ -- QVC and the Fashion Footwear Association of New York (FFANY), building on a 19 year philanthropic relationship supporting breast cancer research, have announced a $140,000 grant to fund research at The Wistar Institute on a specific and deadly form of breast cancer called triple negative.

"The mission of the QVC-FFANY relationship is to support the most promising research with the potential to end breast cancer," said Mike George, president and CEO of QVC. "We are proud to support The Wistar Institute's work as it holds great promise for developing new treatments for breast cancer and saving women's lives." QVC addresses critical health issues for women by working with organizations, like FFANY, to invest in life-saving research.

Close to 300, 000 women are diagnosed with breast cancer each year. Of these, nearly one in four breast cancer cases is classified as triple negative. Triple negative patients have a higher rate of relapse following treatment than other breast cancer patients, and therefore, have lower overall survival rates. 

Triple negative patients have tumors that are missing three proteins found in normal cells. These proteins are critical to deciphering chemical signals, like those from hormones. The laboratory of Dario Altieri, M.D., Director of The Wistar Institute Cancer Center, set out to discover how triple negative breast cancers survive without these important proteins and, in doing so, they found a common factor. Since cells require these signals in order to grow and divide, triple negative breast cancer cells survive by using a gene that is normally "switched off" in adults: Notch-1. While the road to creating therapies is a long one, Altieri is committed to advancing research of Notch- 1 with the ultimate goal of developing new treatments for  triple negative breast cancer. 

"This funding will help us develop better, more targeted therapies against this highly aggressive form of breast cancer," Altieri said. "We are grateful to QVC and FFANY for their vision in ensuring this promising line of research moves forward."

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,164.95 -251.90 -1.45%
S&P 500 1,994.99 -26.26 -1.30%
NASDAQ 4,635.24 -48.1670 -1.03%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs